000733715 000__ 03158cam\a2200469Ii\4500
000733715 001__ 733715
000733715 005__ 20230306141100.0
000733715 006__ m\\\\\o\\d\\\\\\\\
000733715 007__ cr\cn\nnnunnun
000733715 008__ 150825s2015\\\\nyua\\\\o\\\\\001\0\eng\d
000733715 020__ $$a9781493925438$$qelectronic book
000733715 020__ $$a1493925431$$qelectronic book
000733715 020__ $$z9781493925421
000733715 0247_ $$a10.1007/978-1-4939-2543-8$$2doi
000733715 035__ $$aSP(OCoLC)ocn919122978
000733715 035__ $$aSP(OCoLC)919122978
000733715 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dGW5XE$$dN$T$$dOCLCO$$dIDEBK$$dYDXCP$$dCDX$$dSNK$$dUPM$$dCOO$$dOCLCF$$dOCLCO$$dOCLCQ
000733715 049__ $$aISEA
000733715 050_4 $$aTP248.65.P76
000733715 08204 $$a660.6/3$$223
000733715 24500 $$aBiobetters$$h[electronic resource] :$$bprotein engineering to approach the curative /$$cAmy Rosenberg, Barthélemy Demeule, editors.
000733715 264_1 $$aNew York :$$bSpringer,$$c2015.
000733715 300__ $$a1 online resource (xv, 378 pages) :$$bcolor illustrations.
000733715 336__ $$atext$$btxt$$2rdacontent
000733715 337__ $$acomputer$$bc$$2rdamedia
000733715 338__ $$aonline resource$$bcr$$2rdacarrier
000733715 4901_ $$aAAPS advances in the pharmaceutical sciences series,$$x2210-7371 ;$$v19
000733715 500__ $$aIncludes index.
000733715 5050_ $$aIntroduction -- Targeting glucocerebrosidase to macrophages for effective treatment of patients with Gaucher disease: setting the paradigm of a "fit for purpose" approach to enzyme replacement therapy -- Challenges of Enzyme Replacement Therapy: Poor tissue distribution in lysosomal diseases using Pompe disease as a model -- Muscle targeting -- Blood-Brain Barrier Targeting of Therapeutic Lysosomal Enzymes -- Novel Methods for Addressing Immunogenicity in Therapeutic Enzymes -- Structure of monoclonal antibodies -- Prediction of aggregation in vivo by studies of therapeutic proteins in human plasma -- Effect of Hydrolytic Degradation on the In Vivo Properties of Monoclonal Antibodies -- Oxidation of proteins in the in-vivo environment: what we know; what we need to study and potential mitigation strategies -- Molecular assessment: balancing affinity, PK and manufacturability -- Perspectives on engineering biobetter therapeutic proteins with greater stability in inflammatory environments -- Antibody-like molecules designed for superior targeting and pharmacokinetics -- Alternative protein scaffolds as novel biotherapeutics -- Current strategies for pharmacokinetic optimization -- Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect? -- Regulatory considerations for approval of biobetter products.
000733715 506__ $$aAccess limited to authorized users.
000733715 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed August 26, 2015).
000733715 650_0 $$aProtein engineering.
000733715 650_0 $$aProteins$$xBiotechnology.
000733715 650_0 $$aProtein drugs.
000733715 7001_ $$aRosenberg, Amy,$$eeditor.
000733715 7001_ $$aDemeule, Barthélemy,$$eeditor.
000733715 77608 $$iPrint version:$$z9781493925421
000733715 830_0 $$aAAPS advances in the pharmaceutical sciences series ;$$v19.
000733715 852__ $$bebk
000733715 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-1-4939-2543-8$$zOnline Access$$91397441.1
000733715 909CO $$ooai:library.usi.edu:733715$$pGLOBAL_SET
000733715 980__ $$aEBOOK
000733715 980__ $$aBIB
000733715 982__ $$aEbook
000733715 983__ $$aOnline
000733715 994__ $$a92$$bISE